Effects of DNA mass on multiple displacement whole genome amplification and genotyping performance by Bergen, Andrew W et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
BMC Biotechnology
Open Access Methodology article
Effects of DNA mass on multiple displacement whole genome 
amplification and genotyping performance
Andrew W Bergen*1, Ying Qi2,3, Kashif A Haque2,3, Robert A Welch2,3 and 
Stephen J Chanock1,2,4
Address: 1Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA, 2Core 
Genotyping Facility, National Cancer Institute, National Institutes of Health, Gaithersburg, MD, USA, 3Intramural Research Support Program, 
SAIC-Frederick, NCI-FCRDC, Frederick, MD, USA and 4Section on Genomic Variation, Pediatric Oncology Branch, National Cancer Institute, 
National Institutes of Health, Bethesda, MD, USA
Email: Andrew W Bergen* - bergena@mail.nih.gov; Ying Qi - qiy@mail.nih.gov; Kashif A Haque - haquek@mail.nih.gov; 
Robert A Welch - welchr@mail.nih.gov; Stephen J Chanock - chanocks@mail.nih.gov
* Corresponding author    
Abstract
Background: Whole genome amplification (WGA) promises to eliminate practical molecular genetic
analysis limitations associated with genomic DNA (gDNA) quantity. We evaluated the performance of
multiple displacement amplification (MDA) WGA using gDNA extracted from lymphoblastoid cell lines (N
= 27) with a range of starting gDNA input of 1–200 ng into the WGA reaction. Yield and composition
analysis of whole genome amplified DNA (wgaDNA) was performed using three DNA quantification
methods (OD, PicoGreen® and RT-PCR). Two panels of N = 15 STR (using the AmpFlSTR® Identifiler®
panel) and N = 49 SNP (TaqMan®) genotyping assays were performed on each gDNA and wgaDNA sample
in duplicate. gDNA and wgaDNA masses of 1, 4 and 20 ng were used in the SNP assays to evaluate the
effects of DNA mass on SNP genotyping assay performance. A total of N = 6,880 STR and N = 56,448
SNP genotype attempts provided adequate power to detect differences in STR and SNP genotyping
performance between gDNA and wgaDNA, and among wgaDNA produced from a range of gDNA
templates inputs.
Results: The proportion of double-stranded wgaDNA and human-specific PCR amplifiable wgaDNA
increased with increased gDNA input into the WGA reaction. Increased amounts of gDNA input into the
WGA reaction improved wgaDNA genotyping performance. Genotype completion or genotype
concordance rates of wgaDNA produced from all gDNA input levels were observed to be reduced
compared to gDNA, although the reduction was not always statistically significant. Reduced wgaDNA
genotyping performance was primarily due to the increased variance of allelic amplification, resulting in
loss of heterozygosity or increased undetermined genotypes. MDA WGA produces wgaDNA from no
template control samples; such samples exhibited substantial false-positive genotyping rates.
Conclusion: The amount of gDNA input into the MDA WGA reaction is a critical determinant of
genotyping performance of wgaDNA. At least 10 ng of lymphoblastoid gDNA input into MDA WGA is
required to obtain wgaDNA TaqMan® SNP assay genotyping performance equivalent to that of gDNA.
Over 100 ng of lymphoblastoid gDNA input into MDA WGA is required to obtain optimal STR genotyping
performance using the AmpFlSTR® Identifiler® panel from wgaDNA equivalent to that of gDNA.
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Background
The potential for the molecular analysis of human genetic
material has increased enormously with the availability of
the human genome sequence, SNP identification efforts
and the development of high-throughput genotyping
platforms [1]. The expanding demand for single nucle-
otide polymorphism (SNP) genotyping is a consequence
of the recognition that many SNPs will need to be ana-
lyzed to characterize the effects of genes on complex dis-
orders [2], especially when performing whole genome
association studies [3]. With notable exceptions [4], total
DNA requirements for genotyping will increase as the
number of loci investigated expands, despite increased
efficiency of individual genotyping assays. Whole genome
amplification (WGA) is an in vitro procedure to amplify a
genomic DNA (gDNA) sample to generate amplified DNA
(wgaDNA) for further molecular genetic analyses, and has
been considered by some as a potential solution to the
problem of limiting gDNA availability. While PCR-based
methods of WGA have been under continuous develop-
ment for over a decade [5,6], recent application of a highly
processive φ29 DNA polymerase [7], has enabled multiple
displacement amplification (MDA) WGA, an isothermal,
hyperbranching amplification method, with a low level of
locus or allelic bias [8]. Dean [8] and Lovmar [9] have
evaluated the genotyping performance of MDA WGA
using a range of genomic DNA inputs (0.3, 3, 30 and 300
ng, and 0.003, 0.03, 0.3 and 3 ng, respectively). Both
authors focused attention in their evaluation of genotyp-
ing performance on genotyping wgaDNA derived from 3
ng of genomic DNA template. Lasken and Egholm [10]
have recommended 10–100 ng of undegraded gDNA tem-
plate in the MDA WGA reaction to avoid stochastic ampli-
fication. The present study has characterized the yield,
Yield of DNA components of wgaDNA by gDNA input into WGA Figure 1
Yield of DNA components of wgaDNA by gDNA input into WGA. Mean ("+"), Median (middle bar), lower and upper 
quartile (lower and upper end of box), and minimum and maximum of BRCA1 locus equivalents, ssDNA, dsDNA and total 
DNA.BMC Biotechnology 2005, 5:24 http://www.biomedcentral.com/1472-6750/5/24
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composition and genotyping performance of wgaDNA
produced from lymphoblast gDNA templates of 1, 10, 25,
50, 100 and 200 ng. Three DNA quantification methods,
two genotyping methods, and adequate numbers of gen-
otyping assays and DNA samples were used to detect sig-
nificant differences in the yield, composition and
genotyping performance of the wgaDNA produced from
this range of gDNA inputs and to provide additional rec-
ommendations on the amounts of gDNA template to be
used in the MDA WGA reaction.
Results
WGA reaction yield
The yield of H. sapiens PCR-amplifiable (hereafter "RT-
PCR") DNA, ssDNA, dsDNA and total DNA in wgaDNA
by gDNA input mass is presented in Figure 1. RT-PCR
DNA yield increased significantly as gDNA input
increased at each level (all p values ≤ 0.02), where the pro-
portion of the total wgaDNA represented by the RT-PCR
DNA increased from 20% to 46%, at 1 to 200 ng gDNA
input into the WGA reaction, respectively. The yield of
ssDNA decreased, and that of dsDNA increased, as the
gDNA input into the WGA reaction was increased. The
variability in wgaDNA yield by wgaDNA component was
least for total DNA and dsDNA yield, greatest for RT-PCR
yield, and intermediate for ssDNA yield.
Genetic profiling with AmpFlSTR® Identifiler® assay (N = 
15 STR and AMEL)
gDNA exhibited STR genotype completion and concord-
ance rates of 100%, which were significantly greater than
the completion rate exhibited by wgaDNA produced from
1 ng gDNA input and the wgaDNA concordance produced
from all gDNA inputs, respectively (Table 1). wgaDNA
produced from 1 ng gDNA input exhibited significantly
lower STR genotype completion and concordance rates
than did wgaDNA produced from other gDNA inputs,
while wgaDNA produced from 200 ng gDNA input exhib-
ited STR genotyping completion and concordance rates
similar, but not identical to gDNA. 98% of wgaDNA STR
genotypes discordant with gDNA genotypes were
homozygote genotypes, reflecting loss of heterozygosity.
There was a trend for preferential loss of shorter alleles
(129 short alleles/232 total alleles, p = 0.088), but only
for wgaDNA produced from 1 ng of gDNA was this signif-
icant (90 short alleles/145 total alleles, p = 0.0037). Peak
heights were significantly and negatively correlated with
discordance for all gDNA inputs, and for 1, 10 and 100 ng
gDNA inputs separately (Spearman r = -0.58, -0.64, -0.55
and -0.62, with p values <0.0001, = 0.008, = 0.025 and =
0.001, respectively, data not shown), and peak height
ratios of concordant heterozygote wgaDNA genotypes
(from wgaDNA produced from 1 and 50 ng gDNA inputs)
were significantly higher than those from gDNA geno-
types (Wilcoxon's p values ≤ 0.03, data not shown).
The rate of no amplification and discordant genotypes per
STR locus was 0.8% and 4%, respectively. Five STR loci
(TPOX, FGA, D7S820, D13S317 and D18S51) accounted
for the majority of STR no amplification failures (82%)
and discordant (56%) genotypes following WGA (Table
2). The discordance rate for AMEL  genotypes for all
wgaDNA strata was 0.15%, but was 0.73% for wgaDNA
produced from 1 ng gDNA input (Table 2). Composite
genotype quality (GQ) scores for gDNA heterozygote and
homozygote concordant genotypes were significantly bet-
ter (fewer genotypes in the poorer quality categories) than
for concordant wgaDNA heterozygote genotypes at all
gDNA input levels and for concordant wgaDNA homozy-
gote genotypes produced from 1, 100 and 200 ng gDNA
input levels, respectively (Table 3). wgaDNA heterozygote
and homozygote concordant genotypes produced from 1
ng gDNA input exhibited significantly reduced GQ scores
compared to wgaDNA heterozygote and homozygote
Table 1: STR genotyping performance
gDNA Input 
(ng)
Completed1 % 
Completion
No 
Amplification
GQ<0.252 Concordant % 
Concordance
Discordant 
Genotypes
% 
Discordance
gDNA 864 100.03 0 13 851 100.04 00 . 0
1 821 95.0 43 70 638 80.1 150 19.0
10 862 99.8 2 9 830 97.1 25 2.9
25 863 99.9 1 22 823 97.7 19 2.3
50 863 99.9 1 15 836 98.6 12 1.4
100 861 99.7 3 11 826 96.8 27 3.2
200 864 100.0 0 0 858 99.3 6 0.7
1N = 27 gDNA or wgaDNA samples were genotyped in duplicate using the AmpFlSTR® Identifiler® assay for N = 864 attempted genotypes/sample. 
2A Genotype Quality Score (GQ) of <0.25 indicates a STR genotype with a Genotype Quality Score beloew the calling threshold of GeneMapper 
v3.0 software. 3gDNA exhibited significantly greater STR genotype completion rate than did 1 ng gDNA input (p < 0.001). 4gDNA exhibited 
significantly greater STR genotype concordance rates compared to wgaDNA (p < 0.0001, except for 50 ng gDNA input, with p = 0.001, and 200 ng 
gDNA input, p = 0.03).BMC Biotechnology 2005, 5:24 http://www.biomedcentral.com/1472-6750/5/24
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concordant genotypes produced from all other gDNA
input levels, except for wgaDNA homozygote concordant
genotypes produced from 200 ng gDNA (Table 3). GQ
scores of discordant homozygote wgaDNA genotypes
were significantly worse than those for concordant
homozygote wgaDNA genotypes at all gDNA input levels
except 50 ng (p = 0.02 for 25 ng gDNA input, all other p
< 0.0001, data not shown).
SNP genotyping with the TaqMan® assay (N = 49 SNPs)
Results of genotyping using N = 49 TaqMan® SNP geno-
typing assays with 1, 4 and 20 ng of gDNA and wgaDNA
using 1, 10, 25, 50, 100 and 200 ng of gDNA input into
the WGA reaction are summarized in Table 4. We
observed a TaqMan® SNP genotype completion rate of
>99.55%, an undetermined rate of <0.45%, zero discord-
ant genotypes and zero "no amplification failures" in
7938 attempted TaqMan® SNP genotypes using gDNA
template in the TaqMan® SNP assay. No significant differ-
ences in genotyping performance between gDNA tem-
plate inputs into the TaqMan® SNP assay were observed
(Table 4). In pairwise tests, gDNA exhibited a significantly
higher TaqMan® SNP genotype completion rate due to sig-
nificantly decreased undetermined TaqMan® SNP geno-
types, compared to wgaDNA produced from 1 ng of
gDNA input for all wgaDNA template inputs into Taq-
Man® SNP genotyping, and when compared to wgaDNA
produced from 50 and 100 ng of gDNA input when using
1 or 4 ng of wgaDNA template input into the TaqMan®
SNP assay. Over all gDNA and wgaDNA strata, we
observed significantly reduced SNP genotyping perform-
ance when using 1 ng of gDNA or wgaDNA in TaqMan®
SNP genotyping assays with respect to completion rate,
due to a significant increase in the undetermined geno-
type rate (Table 4). However, genotype concordance rates
were not significantly different among the three DNA
(gDNA or wgaDNA) input levels into the TaqMan® SNP
assay, although there was a significant decrease in the con-
cordance rate of 1 ng wgaDNA produced from 1 ng gDNA
into the TaqMan® SNP assay, when compared to 1 ng
wgaDNA produced from 10, 50 and 100 ng of gDNA
input (Table 4).
Predictors of wgaDNA SNP genotyping performance
We were interested to identify parameters from the Core
Genotyping Facility's standard DNA sample handling
protocol that might be predictive of the SNP genotyping
performance of wgaDNA. We performed exploratory cor-
relation analysis among measures of wgaDNA yield (RT-
PCR, ssDNA, dsDNA, total DNA, ratio of RT-PCR to
dsDNA) and genotyping performance (concordance and
completion rates for AmpFlSTR® Identifiler™ and TaqMan®
SNP assay genotyping) within gDNA input strata. Meas-
ures of wgaDNA yield (especially the ratio of RT-PCR to
dsDNA and total DNA) and genotyping performance were
observed to be highly correlated with one another (92%,
3% and 5% of 162 pairwise correlations were statistically
significant, trending and non-significant, respectively).
We then performed linear regression analysis with the
dependent variables "SNP completion rate" and "SNP
Table 2: STR genotyping failures by locus
gDNA Input 
(ng)
Failure Type Genotype 
Failures1
L12 L2 L3 L4 L5 L6 L7 L8 L9 L10 L11 L12 L13 L14 L15 L16
g D N A N o  A m p . 0 000000000 0 0 0 0 0 0 0
D i s c . 0 000000000 0 0 0 0 0 0 0
1 N o  A m p . 4 3 500300700 3 5 0 1 5 1 1 3
D i s c . 1 5 0 1 1 3 9 1 0 4 5 1 3 9 252 292 471 16
1 0 N o  A m p . 2 100100000 0 0 0 0 0 0 0
D i s c . 2 5 200510201 0 7 1 5 0 0 1
2 5 N o  A m p . 1 000000000 0 0 0 1 0 0 0
D i s c . 1 9 411002200 0 2 0 3 2 1 1
5 0 N o  A m p . 1 000000000 0 0 0 1 0 0 0
D i s c . 1 2 001300120 0 0 0 2 1 1 1
1 0 0 N o  A m p . 3 000100000 0 0 1 1 0 0 0
D i s c . 2 7 550201216 0 0 2 1 2 0 0
2 0 0 N o  A m p . 0 000000000 0 0 0 0 0 0 0
D i s c . 6 110200000 0 2 0 0 0 0 0
No Amp. Total 23 10 11 22 5 8 20 12 9 5 33 12 35 12 13 9
Discordant Total 600500700 3 5 1 1 8 1 1 3
1The number of attempted genotypes for all DNA inputs is N = 864. No amplification (No Amp.) genotypes reduce the number of genotypes 
available for concordance analysis. 2Loci 1–16 = TPOX, D2S1338, D3S1358, FGA, D5S818, CSF1PO, D7S820, D8S1179, TH01, vWA, D13S2317, 
D16S539, D18S51, D19S433, D21S11, AMEL.BMC Biotechnology 2005, 5:24 http://www.biomedcentral.com/1472-6750/5/24
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concordance rate", in order to identify WGA reaction,
wgaDNA yield and STR genotyping performance factors
that are significantly associated with wgaDNA SNP geno-
typing performance. Independent variables included:
gDNA input, STR completion rate, concordance rate, GQ
score, peak height, and RT-PCR wgaDNA yield. "STR com-
pletion rate" was a highly significant factor in both SNP
rate models (p < 0.0001), and "STR concordance rate" and
"GQ score" were significant factors in the SNP
concordance rate model (p = 0.0008 and 0.045, respec-
tively). The variable "gDNA input" into the WGA reaction
was significant only in those models incorporating the 1
ng gDNA input strata.
WGA yield and genotyping performance with no template 
control (NTC) samples
No template control (NTC) input samples, i.e., where no
gDNA was used in the WGA reaction, yielded substantial
amounts of wgaDNA, similar in quantity to the total
wgaDNA obtained with gDNA inputs, but with a substan-
tially higher proportion of ssDNA than with gDNA inputs
(Table 5). The wgaDNA produced from the NTC samples
in the 1, 50 and 100 ng gDNA input strata exhibited mean
RT-PCR results that were greater than zero (Table 5). We
observed N = 35 STR peaks with a signal strength > 50
RFUs that fell within the expected base-pair range of an
AmpFlSTR® Identifiler™ locus allele from the wgaDNA
produced from the NTC gDNA and wgaDNA samples for
an overall false positive STR genotyping rate of 4.2%
(Table 5). While these false positive STR peaks fulfill the
criteria for valid AmpFlSTR® Identifiler™ STR alleles, they
are characterized by low heterozygosity (2 observed versus
26 expected heterozygote genotypes), moderate signal
strength (median amplitude = 357 RFUs), and representa-
tion of 12 out of 15 AmpFlSTR® Identifiler™ STR loci. The
50 and 100 ng gDNA input strata (Table 5) and three STR
loci (D2S1338, D8S1179 and FGA)account for the
majority (66% and 51%, respectively) of the wgaDNA
false positive STR genotypes produced from the NTC
samples.
In N = 7056 TaqMan SNP genotype attempts with
wgaDNA produced from the NTC samples, 80%, 14.5%
and 5.5% of the resulting datapoints were incorporated
Table 3: Genotype Quality (GQ) scores of concordant STR genotypes
gDNA Input (ng) GQ1Category, Heterozygotes
I II III Total
gDNA 5 53 580 6382
1 43 137 256 4363
10 27 140 451 618
25 26 126 463 615
50 21 130 474 625
100 25 110 482 617
200 78 31 537 646
Total 225 727 3243 4195
gDNA Input (ng) GQ Category, Homozygotes
I II III Total
gDNA 0 9 204 2134
19 2 5 1 6 8 2 0 2 5
10 2 8 202 212
25 1 8 199 208
50 4 11 196 211
100 8 10 191 209
200 8 20 184 212
Total 32 91 1344 1467
1Category I = GQ scores, originally ≥ 0.25 and <0.40, that have been successfully edited; Category II = GQ scores ≥ 0.40 and ≤ 0.50; Category III = 
GQ scores ≥ 0.79 and ≤ 0.90. 2GQ score distribution, heterozygote genotypes, gDNA versus all wgaDNA, p < 0.0001. 3GQ score distribution, 
heterozygote genotypes, wgaDNA produced from 1 ng gDNA input versus other gDNA inputs, p < 0.0001.4GQ score distribution, homozygote 
genotypes, gDNA versus wgaDNA produced from 1, 100, 200 ng gDNA input, p < 0.0001, 0.01, 0.0001, respectively. 5GQ score distribution, 
homozygote genotypes, wgaDNA produced from 1 ng gDNA input versus 10, 25, 50, 100 ng gDNA inputs, p = 0.0003, 0.0001, 0.009, 0.02, 
respectively.BMC Biotechnology 2005, 5:24 http://www.biomedcentral.com/1472-6750/5/24
Page 6 of 11
(page number not for citation purposes)
into the no amplification (NTC) cluster, into a genotype
cluster ("false positive SNP genotypes"), and into the
undetermined genotype space of the two color TaqMan®
SNP genotyping assay plot, respectively (Table 6). The
number of false positive and undetermined SNP geno-
types from the wgaDNA produced from the NTC samples
increased significantly with increasing amounts of
wgaDNA input into the TaqMan® SNP assay (Table 6). The
majority (96.4%) of these false positive SNP genotypes
from NTC samples were homozygotes (Table 6), signifi-
cantly more allele 2 alleles were observed than allele 1
alleles (Table 6), and all N = 49 TaqMan® SNP assays
exhibited false positive SNP genotypes (data not shown).
wgaDNA NTC samples from the gDNA input strata of 1,
50 and 100 ng exhibited significantly greater numbers of
false positive and undetermined SNP genotypes than did
the wgaDNA NTC samples from the gDNA input strata of
10, 25 and 200 ng (Table 6).
Discussion
wgaDNA may not be suitable for STR genotyping
wgaDNA STR genotyping completion rates reach that of
gDNA at the 10 ng gDNA input level into WGA. However,
the wgaDNA STR concordance rate is significantly worse
than that of gDNA, even with 200 ng of gDNA input into
the WGA reaction (Table 1). Thus, the use of MDA
wgaDNA for accurate STR genotyping will require larger
amounts of input gDNA into the WGA than have been
recommended in the past [8,10]. In the absence of suffi-
cient gDNA template for MDA WGA, investigators face the
tradeoff of no data, or data with increased loss of
heterozygosity, such as that observed with MDA wgaDNA
produced from low mass gDNA templates [11,12].
Development of laboratory and data analysis protocols
optimized for STR genotyping of MDA wgaDNA may be
required before MDA wgaDNA can be routinely used for
STR genotyping. Thus, it might be prudent to adjust geno-
Table 4: SNP genotyping performance
gDNA Input 
(ng)
Completed 
Genotypes1
% 
Completion
Undeter. 
Genotypes
% Undeter. No Amp. % No Amp. Concordant 
Genotypes
% 
Concordance
Discordant 
Genotypes
% 
Discordance
1 ng gDNA or wgaDNA input into TaqMan® SNP genotype assay2,3
gDNA 2636 99.62 10 0.38 0 0 2636 100.00 0 0.00
1 25524 96.45 945 3.55 0 0 2546 99.76 68 0.24
10 2627 99.28 19 0.72 0 0 2627 100.00 0 0.00
25 2636 99.62 10 0.38 0 0 2635 99.96 1 0.04
50 2614 98.79 316 1.17 1 0.04 2614 100.00 0 0.00
100 2620 99.02 256 0.94 1 0.04 2620 100.00 0 0.00
200 2623 98.07 21 0.79 2 0.08 2622 99.96 1 0.04
4 ng gDNA or wgaDNA into TaqMan® SNP genotype assay4
gDNA 2634 99.55 12 0.45 0 0.00 2634 100.00 0 0.00
1 25894 97.85 555 2.08 2 0.08 2586 99.88 3 0.12
10 2628 99.32 17 0.64 1 0.04 2627 99.96 1 0.04
25 2629 99.36 14 0.53 3 0.11 2629 100.00 0 0.00
50 2621 99.06 235 0.87 2 0.08 2619 99.92 2 0.08
100 2619 98.98 205 0.76 77 0.26 2617 99.92 2 0.08
200 2635 99.4 10 0.38 1 0.04 2632 99.89 3 0.11
20 ng gDNA or wgaDNA into TaqMan® SNP genotype assay
gDNA 2637 99.66 9 0.34 0 0 2637 100.00 0 0.00
1 25694 97.09 775 2.91 0 0 2566 99.88 3 0.12
10 2633 99.51 13 0.49 0 0 2633 100.00 0 0.00
25 2639 99.74 7 0.26 0 0 2638 99.96 1 0.04
50 2633 99.51 13 0.49 0 0 2632 99.96 1 0.04
100 2630 99.40 16 0.60 0 0 2629 99.96 1 0.04
200 2635 99.55 11 0.42 0 0 2632 99.89 3 0.11
1There were N = 27 samples gentoyped in duplicate at N = 49 SNPs for N = 2,646 attempted genotypes/sample. 21 versus 4 ng gDNA or wgaDNA 
input, SNP genotyping rates: completion, p = 0.0178; undetermined, p = 0.0022; no amplification, p = 0.0139; concordance, p = n.s. 31 versus 20 ng 
gDNA or wgaDNA input, SNP genotyping rates: completion, p = 0.0004; undetermined, p = 0.0008; no amplification, p = n.s.; concordance, p = n.s. 
44 versus 20 ng gDNA or wgaDNA input, SNP genotyping rates: completion, p = n.s.; undetermined, p = n.s.; no amplification, p = 0.0002; 
concordance, p = n.s. 5gDNA versus wgaDNA produced from 1 ng gDNA input, SNP genotype completion rates, p < 0.0001. 6gDNA versus 
wgaDNA produced from 50 and 100 ng gDNA input, p ≤ 0.05. 7gDNA versus wgaDNA produced from 100 ng gDNA input, p = 0.02. 8wgaDNA 
produced from 1 ng versus gDNA and wgaDNA produced from 10, 50 and 100 ng of gDNA input, p ≤ 0.014.BMC Biotechnology 2005, 5:24 http://www.biomedcentral.com/1472-6750/5/24
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type analysis algorithms before application of the Amp-
FlSTR®  Identifiler™ panel to wgaDNA for forensic
purposes, as has been recommended for the analysis of
STR profiles from highly limited unamplified gDNA tem-
plate [13], or to utilize analysis methods that incorporate
STR genotyping error, as has been recommended for the
analysis of STR linkage scan data [14].
wgaDNA is a suitable template for SNP genotyping
wgaDNA produced from ≥ 10 ng of gDNA input into the
WGA reaction exhibits robust wgaDNA TaqMan® SNP
assay genotyping performance rates, similar to that of
gDNA TaqMan® SNP assay genotyping performance rates.
1 ng of wgaDNA template into the TaqMan® SNP assay
exhibits significantly reduced TaqMan® SNP assay geno-
typing performance compared to both 4 and 20 ng
wgaDNA templates into the TaqMan® SNP assay. 4 ng
wgaDNA template into the TaqMan® SNP assay exhibits a
significantly increased no amplification rate over both 1
and 20 ng wgaDNA templates, although no amplification
rates are very low (all <0.01%) for all three wgaDNA tem-
plate inputs into the TaqMan® SNP assay. These results
suggest that optimal TaqMan® SNP assay genotyping per-
formance, i.e., minimal wgaDNA TaqMan® no amplifica-
tion and undetermined genotyping rates, should be
expected for wgaDNA inputs greater than 4 ng.
False positive NTC sample SNP genotypes
A non-zero RT-PCR yield and significantly increased num-
bers of observed false positive genotypes in wgaDNA from
NTC samples in the 1, 50 and 100 ng gDNA input strata
are consistent with human gDNA contamination of these
gDNA input strata. However, we also observed signifi-
cantly more false positive and undetermined SNP assay
genotypes in each of the 10, 25 and 200 ng gDNA input
strata (the apparently uncontaminated strata) than in the
gDNA strata (all p < 0.0001), concordant with the hypoth-
esis that a portion of the NTC TaqMan® genotypes may be
due to degradation of TaqMan® SNP assay reagents. Thus,
contamination of NTC samples with gDNA and TaqMan®
SNP assay probe oligonucleotide degradation during the
genotyping of wgaDNA are both associated with false-
positive TaqMan® SNP assay genotypes.
Limitations
This study is distinguished by the use of multiple assays to
estimate wgaDNA yield and composition, the use of STR
and SNP genotyping assays that have been validated by
sequencing the same DNA samples used in this study, and
the use of an adequate number of samples and assays to
provide statistical power to detect small differences in the
genotyping performance of wgaDNA and gDNA, when
using 1–200 ng of gDNA as template in the WGA reaction.
Table 5: Yield and STR genotypes from NTC samples
gDNA Input (ng) Yield
N Mean RT-PCR (ng) Median ssDNA (%) Median total DNA (ng)
g D N A ----
1 4 135 51.5 12230
10 4 0 50.8 11771
25 4 0 55 12340
50 4 24 45 12395
100 4 220 48.6 12686
200 4 0 54 14879
STR
gDNA Input (ng) N False Positive Rate (%)1 Mean Height Allele 1 Mean Height Allele 2
gDNA 64 6 93 93
1 128 5 2185 2199
10 128 0 - -
25 128 0 - -
50 128 92 375 393
100 128 92 571 571
200 128 2 2360 2360
1The number of "attempted" AmpFlSTR® Identifiler™ panel genotypes using gDNA NTCs and wgaDNA from NTC samples is 832 [two NTC DNA 
samples genotyped for gDNA in duplicate (64 possible genotype bins), and four wgaDNA samples from NTCs for each gDNA input level genotyped 
in duplicate (768 possible genotype bins)]. 2There were significantly more false positive STR genotypes in the wgaDNA produced from 50 ng and 
100 ng gDNA inputs compared to the wgaDNA produced from 200 ng gDNA input (p = 0.01 and 0.02).BMC Biotechnology 2005, 5:24 http://www.biomedcentral.com/1472-6750/5/24
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Nevertheless, there are limitations, with respect to
generalizing to all gDNA templates, MDA protocols and
genotyping methods, respectively.
The gDNA used in this study was extracted from lymphob-
lasts and samples from most studies are unlikely to be of
such high quality. Using a model system to evaluate the
effect of significant gDNA degradation on the WGA reac-
tion, it has been shown that MDA wgaDNA produced
from irradiated gDNA exhibits significantly reduced yield
and genotyping performance compared to MDA wgaDNA
produced from unirradiated gDNA [15]. The yield and
genotyping differences observed in wgaDNA produced
from high quality (this study) and low quality [15] gDNA
samples suggest that those gDNA samples with DNA
extraction, storage and usage histories that have reduced
Table 6: SNP genotypes from NTC samples
gDNA Input (ng) Allele 1 Allele 2 Both No Amp. Undeter. Total
1 ng gDNA or wgaDNA input into TaqMan® SNP genotype assay1
g D N A 0 2 03 8 553 9 2
13 27 29 2 315 19 392
10 6 12 1 362 11 392
25 6 10 0 364 12 392
503 38 49 5 266 34 392
1003 26 48 2 289 27 392
2 0 0 1 82 0 03 5 133 9 2
Total 121 1702 10 2332 111 2744
4 ng gDNA or wgaDNA input into TaqMan® SNP genotype assay1
g D N A 1 2 03 8 183 9 2
13 39 36 2 292 23 392
10 7 7 0 360 18 392
25 6 18 1 349 18 392
503 50 43 0 275 24 392
1003 26 43 2 274 47 392
2 0 0 2 63 8 33 1 693 9 2
Total 155 1872 8 2247 147 2744
20 ng gDNA or wgaDNA input into TaqMan® SNP genotype assay1
g D N A 0 1 03 8 383 9 2
13 29 37 2 297 27 392
10 11 15 1 346 19 392
25 8 9 0 364 11 392
503 37 54 4 263 34 392
1003 25 55 2 277 33 392
200 38 42 10 284 18 392
Total 148 2132 19 2214 150 2744
1A significant increase in the number of false positive and undetermined SNP genotypes is observed with increasing amounts of wgaDNA template: 
11.0%, 12.8% and 13.8% for 1, 4 and 20 ng wgaDNA input, respectively, p = 0.045, 1 versus 4 ng wgaDNA input, and p = 0.0014, 1 versus 20 ng 
wgaDNA input, p = 0.0046 test for trend, 1 vs. 4 vs 20 ng wgaDNA input, for false positive genotypes; 4.0%, 5.34% and 5.47%, respectively, p = 
0.026, 1 versus 4 ng, and p = 0.0159, 1 versus 20 ng, p = 0.0153 for trend, for undetermined genotypes. 2Significantly more allele 2 NTC TaqMan® 
SNP assay alleles were observed than allele 1 NTC TaqMan® assay alleles (p = 0.006, 0.091 and 0.001 for 1, 4 and 20 ng gDNA and wgaDNA input 
into the TaqMan® SNP assays, respectively), where the fluorescent label was 6-Fam for allele 1, and Vic for allele 2, in all the TaqMan® SNP assays in 
this study. 3The gDNA input strata of 1, 50 and 100 ng exhibited significantly greater numbers of false positive and undetermined SNP genotypes 
than did the gDNA input strata of 10, 25 and 200 ng (p < 0.0001).BMC Biotechnology 2005, 5:24 http://www.biomedcentral.com/1472-6750/5/24
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concentrations of high molecular weight DNA in the sam-
ple are likely to exhibit less than optimal MDA wgaDNA
yield and genotyping performance.
While only one commercially available MDA WGA proto-
col was used in this study, we have evaluated two MDA
WGA protocols on gDNA extracted from multiple tissue
types, and no systematic significant differences in geno-
typing performance between the two MDA WGA proto-
cols was observed [16]. STR and SNP genotyping
performance of MDA wgaDNA derived from 4 ng of
gDNA input in that study is seen to be intermediate
between the genotyping performance of MDA wgaDNA
produced from 1 ng and 10 ng in this study. Alternative
WGA technologies that can prepare wgaDNA of accepta-
ble quality from gDNA with reduced complexity or con-
centration may be required for some degraded gDNA
samples. For example, PCR-based methods that reduce
genome complexity before amplification are one
approach [6,17], and methods that combines genome cir-
cularization with φ29 DNA polymerase are another [18].
Finally, we applied two commonly used genotyping
methods to evaluate the genotyping performance of
wgaDNA in this study. Different genotyping technologies
may be better suited to produce optimal genotyping per-
formance with wgaDNA than the two we evaluated. For
STRs, genotyping panels designed for linkage scanning
usually employ lower levels of multiplexing and use larger
amounts of DNA template than do STR panels designed
for forensic analysis, such as the AmpFlSTR® Identifiler™.
E.g., reported MDA wgaDNA STR genotype discordance
rates using linkage scan STR panels [19,20] and forensic
STR panels [15,16,21] range from ~0% to ~6% and the
average rate of the five studies cited (2.0%) is similar to
the rates observed in this study. For SNPs, those genotyp-
ing technologies with redundant data sampling for SNP
genotype determination, such as minisequencing [22],
the Golden Gate™ assay [23] or the GeneChip® variant
detection array [24], may be more resistant to SNP
genotype failure when genotyping wgaDNA [9,25,26]
than those SNP genotyping technologies with single data
point genotype determination [27]. However, in a recent
direct comparison of Golden Gate™, TaqMan®  and
Invader™ SNP assays, with gDNA extracted from lym-
phoblasts using an organic extraction method and MDA
wgaDNA produced from 20 ng of this gDNA, the Golden
Gate™ assay exhibited a higher exclusion rate of DNA sam-
ples, and a higher completion rate and lower concordance
rate on the remaining samples, than exhibited by the Taq-
Man® and Invader™ SNP assays [28]. For all three SNP gen-
otyping technologies evaluated, the genotyping
performance of gDNA was observed to be significantly
better than that of MDA wgaDNA [28].
Conclusion
We have evaluated the yield, composition and genotyping
performance of wgaDNA based on a range of high-quality
lymphoblastoid gDNA templates between 1 and 200 ng
in order to provide empirical data on the performance of
MDA WGA technology. A detailed analysis of the
observed genotyping failures has been performed to facil-
itate an understanding of the reduction in genotyping per-
formance likely to be observed when genotyping wgaDNA
produced from a range of gDNA inputs. Increasing gDNA
input from 1 – 200 ng in the MDA WGA reaction
improves the yield of H. sapiens PCR-amplifiable DNA
and improves the genotyping performance of the Amp-
FlSTR® Identifiler® assay. More than 100 ng of high quality
gDNA template into the MDA WGA reaction is required in
order to observe MDA wgaDNA AmpFlSTR® Identifiler®
STR genotyping performance similar to that observed with
gDNA. At least 10 ng of high quality lymphoblastoid
gDNA template into the WGA reaction is required to
observe optimal TaqMan® SNP genotyping performance
from MDA wgaDNA.
Methods
gDNA samples
N = 22 lymphoblast genomic DNA (gDNA) samples were
obtained directly from the Coriell Cell Repository (Cam-
den, NJ); these samples were from individuals within the
SNP500 Cancer dataset [29]. Each gDNA was quantified
by UV spectroscopy, the PicoGreen®  assay (Molecular
Probes, Eugene, OR), and a Real-Time (RT) TaqMan® assay
specific to human DNA [30]. Five of twenty-two Coriell
Cell Repository lymphoblast gDNA samples were repli-
cated for a total of N = 27 lymphoblast gDNA samples
subjected to WGA and post-WGA analysis in order to
increase statistical power to detect genotyping error.
Whole genome amplification
1, 10, 25, 50, 100 and 200 ng of each gDNA sample was
used as template and amplified according to the Genom-
iPhi™ WGA protocol (1X). The 200 ng gDNA template
sample was amplified separately after evaluation of the
genotyping performance of the wgaDNA produced from 1
– 100 ng gDNA. Each gDNA sample was subjected to the
WGA protocol once; four no gDNA template controls
(NTC) reactions were included at each gDNA input level.
wgaDNA was quantified with OD260, PicoGreen® and RT-
PCR, as was performed for gDNA. The concentrations of
ssDNA, dsDNA, total DNA and human-specific PCR
amplifiable (RT-PCR) DNA in the wgaDNA samples were
estimated as described [16].
AmpFlSTR® Identifiler® assay
300 pg of dsDNA (both gDNA and wgaDNA, as deter-
mined by PicoGreen®) was used as template DNA for
AmpFlSTR®  Identifiler®  assay (Applied Biosystems Inc.,BMC Biotechnology 2005, 5:24 http://www.biomedcentral.com/1472-6750/5/24
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Foster City, CA), and scoring of alleles, assignment of
Genotype Quality scores and calculation of genotype fail-
ure rates were performed as described [16]. Peak height
ratio distributions at a signal strength threshold of = 50
RFUs were evaluated for normality and differences
between assigned and observed GQ score category distri-
butions evaluated using Wilcoxon's rank sum test and
contingency table analyses.
TaqMan® SNP genotype assays
N = 49 TaqMan® (Applied Biosystems Inc., Foster City,
CA) genotyping assays from the publicly available
SNP500 Cancer Database portfolio [29] were chosen as
described [16]. 1.0, 4.0 and 20.0 ng of dsDNA (both
gDNA and wgaDNA, as determined by PicoGreen®) was
used as template for genotyping using the N = 49 Taq-
Man®  assays. Reaction and cycling conditions, control
samples, fluorescence detection and genotype cluster
assignment were performed as described [16]. SNP geno-
type completion, undetermined genotype, no amplifica-
tion, and discordance rates were calculated, with the
wgaDNA discordance rate calculated to be the number of
instances in which a wgaDNA SNP genotype differed from
the scored gDNA SNP genotype. Differences in rates were
evaluated using contingency table analyses.
Data management and analysis
Data was managed using a Sapphire Laboratory Informa-
tion Management System (LabVantage, New Brunswick,
NJ), exported in Microsoft Excel (Redmond, WA) and sta-
tistical analyses (descriptive statistics and tests of normal-
ity, distribution and correlation) were performed using
SAS (Cary, NC) software. Tests of proportion, correlation,
etc., are considered significant at a Type I error level of
0.05, with additional information on p values provided if
appropriate.
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